Literature DB >> 12601352

Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats.

Vicente Lorenzo-Zúñiga1, Ramón Bartolí, Ramón Planas, Alan F Hofmann, Belén Viñado, Lee R Hagey, José M Hernández, Josep Mañé, Marco A Alvarez, Vicente Ausina, Miquel Angel Gassull.   

Abstract

Experiments were performed to test whether conjugated bile acid administration would decrease bacterial overgrowth, bacterial translocation, and endotoxemia in ascitic cirrhotic rats. Cholylsarcosine, a deconjugation-dehydroxylation resistant and cholylglycine, a deconjugation-dehydroxylation susceptible bile acid were used. Rats with CCl(4)-induced cirrhosis and ascites were fed cholylsarcosine, cholylglycine (both at 70 mg/kg/d), or placebo for 2 weeks. Healthy rats, as controls, were treated similarly. In cirrhotic rats receiving placebo, bile secretion from an acute biliary fistula was lower than in healthy rats (27.2 +/- 6.5 vs. 53.0 +/- 3.1 microL/kg/min; mean +/- SE, P<.05). The administration of conjugated bile acids to cirrhotic rats normalized bile secretion (cholylsarcosine, 51.8 +/- 6.29; cholylglycine, 52.72 +/- 8.9 microL/kg/min). Total ileal bacterial content was 6-fold higher in ascitic cirrhotic rats than in healthy rats. Conjugated bile acid administration reduced bacterial content to normal levels. Bacterial translocation was less in cirrhotic animals receiving conjugated bile acids (cholylsarcosine, 33%; cholylglycine, 26%) than in animals receiving placebo (66%). Endotoxemia was decreased in cirrhotic rats by conjugated bile acid feeding (cholylsarcosine, 0.098 +/- 0.002; cholylglycine 0.101 +/- 0.007 EU/mL) compared with placebo (0.282 +/- 0.124, P <.001). Survival was greater in animals receiving conjugated bile acids (cholylsarcosine, 10/15; cholylglycine, 11/15; placebo, 5/15). In conclusion, the administration of conjugated bile acids to ascitic cirrhotic rats increased bile acid secretion, eliminated intestinal bacterial overgrowth, decreased bacterial translocation, decreased endotoxemia, and increased survival. Oral conjugated bile acids may be useful in preventing bacterial translocation, endotoxemia, and spontaneous bacterial perotonitis in cirrhotic patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12601352     DOI: 10.1053/jhep.2003.50116

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  107 in total

1.  Enteropathogenic Escherichia coli inhibits ileal sodium-dependent bile acid transporter ASBT.

Authors:  Fadi Annaba; Zaheer Sarwar; Ravinder K Gill; Amit Ghosh; Seema Saksena; Alip Borthakur; Gail A Hecht; Pradeep K Dudeja; Waddah A Alrefai
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-03-08       Impact factor: 4.052

Review 2.  Alcoholic liver disease: the gut microbiome and liver cross talk.

Authors:  Phillipp Hartmann; Caroline T Seebauer; Bernd Schnabl
Journal:  Alcohol Clin Exp Res       Date:  2015-05       Impact factor: 3.455

Review 3.  Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease.

Authors:  Tiangang Li; John Y L Chiang
Journal:  Hepatobiliary Surg Nutr       Date:  2020-04       Impact factor: 7.293

4.  Insulin-like growth factor I improves intestinal barrier function in cirrhotic rats.

Authors:  V Lorenzo-Zúñiga; C M Rodríguez-Ortigosa; R Bartolí; M-L Martínez-Chantar; L Martínez-Peralta; A Pardo; I Ojanguren; J Quiroga; R Planas; J Prieto
Journal:  Gut       Date:  2006-01-24       Impact factor: 23.059

5.  How bile acids confer gut mucosal protection against bacteria.

Authors:  Alan F Hofmann; Lars Eckmann
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

6.  The role of the gut microbiota in nonalcoholic fatty liver disease.

Authors:  Ahmed Abu-Shanab; Eamonn M M Quigley
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-11-02       Impact factor: 46.802

Review 7.  Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia.

Authors:  Hiroshi Fukui
Journal:  World J Hepatol       Date:  2015-03-27

Review 8.  Mechanisms of weight loss and improved metabolism following bariatric surgery.

Authors:  Christopher M Mulla; Roeland J W Middelbeek; Mary-Elizabeth Patti
Journal:  Ann N Y Acad Sci       Date:  2017-09-03       Impact factor: 5.691

9.  Urinary metabolomics in Fxr-null mice reveals activated adaptive metabolic pathways upon bile acid challenge.

Authors:  Joo-Youn Cho; Tsutomu Matsubara; Dong Wook Kang; Sung-Hoon Ahn; Kristopher W Krausz; Jeffrey R Idle; Hans Luecke; Frank J Gonzalez
Journal:  J Lipid Res       Date:  2009-11-09       Impact factor: 5.922

10.  [Steatohepatitis and cirrhosis: first manifestation 23 years after jejunoileal bypass surgery].

Authors:  Peter Piringer; Robert Buder; Fritz Firlinger; Christine Kapral; Christian Luft; Wolfgang Sega; Friedrich Wewalka; Kurt Lenz
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.